Bio Saga Blog - A Chronicle of Life Sciences & Informatics

Belgian biotech firm Galapagos today announced its BioFocus service division has extended a contract with Amgen through 2012 to include target discovery and validation work. The extension will include the use of BioFocus' target discovery platform to deliver novel targets to support Amgen's therapeutic programs. Galapagos will receive €2 million ($2.6 million) in research fees in the first year, under the terms of the deal. It is also eligible for access fees and milestone payments. Originally forged in 2002, the collaboration between BioFocus, which Galapagos acquired in 2005, and Amgen involves identifying new molecules against drug targets. The partnership was extended in 2006 and 2008. BioFocus' discovery platform includes the use of  in vitro  and cell-based screening, structural biology, and chemogenomic and informatics tools.

BioFocus DPI has partnered with the cancer drug candidate and biomarker company Oncodesign to offer an integrated service platform, Galapagos division BioFocus DPI said today. The agreement will create a service that combines BioFocus DPI's target discovery and screening capabilities with Oncodesign's biomarker and pharmacological services to offer target validation and clinical candidate selection services, the company said. BioFocus DPI offers gene-to-drug candidate discovery services, including in vitro and cell-based screening, chemogenomic and informatics offerings , storage, distribution, and other structural biology and medicinal chemistry services. XTractor Premium - A Platform for discovery , knowledge sharing, analysis and modelling of published biomedical facts. The only Knowledgebase which provides "manually" annotated facts from PubMed on a weekly basis Innovative Features like Semantic Search , Concept Linking , Bibliographic search , Save, ...